Genelux (GNLX) Capital Expenditures (2022 - 2026)
Genelux (GNLX) recorded quarterly Capital Expenditures of $921000.0 in Q1 2026, up 111.24% quarter-over-quarter from $436000.0 in Q4 2025, and up 2970.0% on a YoY basis from $30000.0 in Q1 2025.
Genelux (GNLX) Capital Expenditures (2022 - 2026) Analysis & Trends
Genelux's Capital Expenditures history runs 5 years deep, the most recent figure standing at $921000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 2970.0% year-over-year to $921000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 422.05% YoY), while the FY2025 annual figure was $1.1 million, up 188.19% from the prior year.
- Capital Expenditures was $921000.0 for Q1 2026 at Genelux, up from $436000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $921000.0 in Q1 2026 to a low of $15000.0 in Q1 2022.
- Historically, Capital Expenditures has averaged $245714.3 across 5 years, with a median of $171500.0 in 2024.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures plunged 90.25% in 2024, then surged 2970.0% in 2026.
- A 5-year view of Capital Expenditures shows it stood at $15000.0 in 2022, then soared by 1520.0% to $243000.0 in 2023, then sank by 60.49% to $96000.0 in 2024, then soared by 354.17% to $436000.0 in 2025, then soared by 111.24% to $921000.0 in 2026.
- The last three Capital Expenditures figures came in at $921000.0 (Q1 2026), $436000.0 (Q4 2025), and $517000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 921,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 921,000.00 |
| Mar 31, 2026 | 921,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 243,000.00 |
| Dec 31, 2023 | 243,000.00 |